vs

Side-by-side financial comparison of AMERICAN AXLE & MANUFACTURING HOLDINGS INC (AXL) and NEUROCRINE BIOSCIENCES INC (NBIX). Click either name above to swap in a different company.

AMERICAN AXLE & MANUFACTURING HOLDINGS INC is the larger business by last-quarter revenue ($1.4B vs $805.5M, roughly 1.7× NEUROCRINE BIOSCIENCES INC). NEUROCRINE BIOSCIENCES INC runs the higher net margin — 19.1% vs -5.4%, a 24.5% gap on every dollar of revenue. On growth, NEUROCRINE BIOSCIENCES INC posted the faster year-over-year revenue change (28.3% vs 0.2%). NEUROCRINE BIOSCIENCES INC produced more free cash flow last quarter ($386.0M vs $54.7M). Over the past eight quarters, NEUROCRINE BIOSCIENCES INC's revenue compounded faster (25.0% CAGR vs -7.2%).

American Axle & Manufacturing, Inc. (AAM), headquartered in Detroit, Michigan, is an American manufacturer of automobile driveline and drivetrain components and systems.

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

AXL vs NBIX — Head-to-Head

Bigger by revenue
AXL
AXL
1.7× larger
AXL
$1.4B
$805.5M
NBIX
Growing faster (revenue YoY)
NBIX
NBIX
+28.1% gap
NBIX
28.3%
0.2%
AXL
Higher net margin
NBIX
NBIX
24.5% more per $
NBIX
19.1%
-5.4%
AXL
More free cash flow
NBIX
NBIX
$331.3M more FCF
NBIX
$386.0M
$54.7M
AXL
Faster 2-yr revenue CAGR
NBIX
NBIX
Annualised
NBIX
25.0%
-7.2%
AXL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXL
AXL
NBIX
NBIX
Revenue
$1.4B
$805.5M
Net Profit
$-75.3M
$153.7M
Gross Margin
10.2%
97.8%
Operating Margin
-2.4%
26.2%
Net Margin
-5.4%
19.1%
Revenue YoY
0.2%
28.3%
Net Profit YoY
-449.6%
49.1%
EPS (diluted)
$-0.62
$1.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXL
AXL
NBIX
NBIX
Q4 25
$1.4B
$805.5M
Q3 25
$1.5B
$794.9M
Q2 25
$1.5B
$687.5M
Q1 25
$1.4B
$572.6M
Q4 24
$1.4B
$627.7M
Q3 24
$1.5B
$622.1M
Q2 24
$1.6B
$590.2M
Q1 24
$1.6B
$515.3M
Net Profit
AXL
AXL
NBIX
NBIX
Q4 25
$-75.3M
$153.7M
Q3 25
$9.2M
$209.5M
Q2 25
$39.3M
$107.5M
Q1 25
$7.1M
$7.9M
Q4 24
$-13.7M
$103.1M
Q3 24
$10.0M
$129.8M
Q2 24
$18.2M
$65.0M
Q1 24
$20.5M
$43.4M
Gross Margin
AXL
AXL
NBIX
NBIX
Q4 25
10.2%
97.8%
Q3 25
12.6%
98.2%
Q2 25
13.1%
98.4%
Q1 25
12.3%
98.4%
Q4 24
11.2%
98.5%
Q3 24
11.4%
98.7%
Q2 24
13.3%
98.4%
Q1 24
12.4%
98.5%
Operating Margin
AXL
AXL
NBIX
NBIX
Q4 25
-2.4%
26.2%
Q3 25
3.2%
30.1%
Q2 25
3.6%
21.2%
Q1 25
3.0%
4.1%
Q4 24
2.6%
22.6%
Q3 24
2.8%
29.5%
Q2 24
5.3%
24.6%
Q1 24
4.8%
19.3%
Net Margin
AXL
AXL
NBIX
NBIX
Q4 25
-5.4%
19.1%
Q3 25
0.6%
26.4%
Q2 25
2.6%
15.6%
Q1 25
0.5%
1.4%
Q4 24
-1.0%
16.4%
Q3 24
0.7%
20.9%
Q2 24
1.1%
11.0%
Q1 24
1.3%
8.4%
EPS (diluted)
AXL
AXL
NBIX
NBIX
Q4 25
$-0.62
$1.49
Q3 25
$0.07
$2.04
Q2 25
$0.32
$1.06
Q1 25
$0.06
$0.08
Q4 24
$-0.11
$1.00
Q3 24
$0.08
$1.24
Q2 24
$0.15
$0.63
Q1 24
$0.17
$0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXL
AXL
NBIX
NBIX
Cash + ST InvestmentsLiquidity on hand
$708.9M
$713.0M
Total DebtLower is stronger
$4.0B
Stockholders' EquityBook value
$640.0M
$3.3B
Total Assets
$6.7B
$4.6B
Debt / EquityLower = less leverage
6.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXL
AXL
NBIX
NBIX
Q4 25
$708.9M
$713.0M
Q3 25
$714.1M
$340.2M
Q2 25
$586.5M
$264.0M
Q1 25
$549.2M
$194.1M
Q4 24
$552.9M
$233.0M
Q3 24
$542.5M
$349.1M
Q2 24
$519.9M
$139.7M
Q1 24
$469.8M
$396.3M
Total Debt
AXL
AXL
NBIX
NBIX
Q4 25
$4.0B
Q3 25
$2.6B
Q2 25
$2.6B
Q1 25
$2.6B
Q4 24
$2.6B
Q3 24
$2.6B
Q2 24
$2.7B
Q1 24
$2.7B
Stockholders' Equity
AXL
AXL
NBIX
NBIX
Q4 25
$640.0M
$3.3B
Q3 25
$718.4M
$3.0B
Q2 25
$673.0M
$2.7B
Q1 25
$596.3M
$2.5B
Q4 24
$562.8M
$2.6B
Q3 24
$616.3M
$2.7B
Q2 24
$609.6M
$2.5B
Q1 24
$621.4M
$2.4B
Total Assets
AXL
AXL
NBIX
NBIX
Q4 25
$6.7B
$4.6B
Q3 25
$5.3B
$4.3B
Q2 25
$5.3B
$3.9B
Q1 25
$5.1B
$3.7B
Q4 24
$5.1B
$3.7B
Q3 24
$5.3B
$3.5B
Q2 24
$5.3B
$3.3B
Q1 24
$5.4B
$3.5B
Debt / Equity
AXL
AXL
NBIX
NBIX
Q4 25
6.31×
Q3 25
3.61×
Q2 25
3.86×
Q1 25
4.38×
Q4 24
4.58×
Q3 24
4.28×
Q2 24
4.42×
Q1 24
4.40×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXL
AXL
NBIX
NBIX
Operating Cash FlowLast quarter
$120.5M
$388.4M
Free Cash FlowOCF − Capex
$54.7M
$386.0M
FCF MarginFCF / Revenue
4.0%
47.9%
Capex IntensityCapex / Revenue
4.8%
0.3%
Cash ConversionOCF / Net Profit
2.53×
TTM Free Cash FlowTrailing 4 quarters
$155.1M
$743.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXL
AXL
NBIX
NBIX
Q4 25
$120.5M
$388.4M
Q3 25
$143.3M
$227.5M
Q2 25
$91.9M
$102.0M
Q1 25
$55.9M
$64.8M
Q4 24
$151.2M
$242.5M
Q3 24
$143.6M
$158.0M
Q2 24
$142.8M
$64.6M
Q1 24
$17.8M
$130.3M
Free Cash Flow
AXL
AXL
NBIX
NBIX
Q4 25
$54.7M
$386.0M
Q3 25
$79.2M
$214.3M
Q2 25
$34.6M
$89.5M
Q1 25
$-13.4M
$54.1M
Q4 24
$73.2M
$235.2M
Q3 24
$70.4M
$149.9M
Q2 24
$94.0M
$53.0M
Q1 24
$-30.2M
$119.1M
FCF Margin
AXL
AXL
NBIX
NBIX
Q4 25
4.0%
47.9%
Q3 25
5.3%
27.0%
Q2 25
2.3%
13.0%
Q1 25
-0.9%
9.4%
Q4 24
5.3%
37.5%
Q3 24
4.7%
24.1%
Q2 24
5.8%
9.0%
Q1 24
-1.9%
23.1%
Capex Intensity
AXL
AXL
NBIX
NBIX
Q4 25
4.8%
0.3%
Q3 25
4.3%
1.7%
Q2 25
3.7%
1.8%
Q1 25
4.9%
1.9%
Q4 24
5.6%
1.2%
Q3 24
4.9%
1.3%
Q2 24
3.0%
2.0%
Q1 24
3.0%
2.2%
Cash Conversion
AXL
AXL
NBIX
NBIX
Q4 25
2.53×
Q3 25
15.58×
1.09×
Q2 25
2.34×
0.95×
Q1 25
7.87×
8.20×
Q4 24
2.35×
Q3 24
14.36×
1.22×
Q2 24
7.85×
0.99×
Q1 24
0.87×
3.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXL
AXL

Driveline$748.4M54%
Other$345.7M25%
Metal Forming$289.8M21%

NBIX
NBIX

INGREZZA Net Product Sales$653.8M81%
CRENESSITY Net Product Sales$135.4M17%
Other Income$12.6M2%
Collaboration Revenue$7.2M1%

Related Comparisons